Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.00K | — | — | — | — | $0.00 | $0.00 | — | — | — |
| Gross profit | $5.00K | — | — | — | — | — | — | — | — | — |
| Gross margin | 100.0% | — | — | — | — | — | — | — | — | — |
| Operating income | -$1.92M | -$1.80M | -$4.52M | -$3.94M | -$15.1M | -$12.1M | -$27.5M | -$11.5M | -$12.1M | -$14.0M |
| Operating margin | -38430.4% | — | — | — | — | — | — | — | — | — |
| Net income | -$1.92M | -$1.86M | -$3.77M | -$3.36M | -$14.4M | -$11.4M | -$27.4M | -$11.1M | -$11.9M | -$13.6M |
| Net margin | -38341.3% | — | — | — | — | — | — | — | — | — |
| EPS (diluted) | -$0.07 | -$0.06 | -$0.71 | -$0.70 | -$2.54 | -$0.75 | -$34.05 | -$8.48 | -$96.78 | -$10.36 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.16M | -$1.65M | -$3.71M | -$2.75M | -$3.14M | -$8.72M | -$9.61M | -$8.06M | -$11.2M | -$11.4M |
| Capital expenditures | $23.8K | $20.6K | — | — | — | — | — | $2.78K | $3.24K | — |
| Free cash flow | -$2.18M | -$1.68M | — | — | — | — | — | -$8.07M | -$11.2M | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.07M | $2.85M | $1.74M | $692K | $15.4M | $16.5M | $6.50M | $4.71M | $1.19M | $5.54M |
| Total assets | $2.36M | $2.98M | $12.5M | $10.9M | $25.2M | $26.5M | $8.62M | $5.79M | $3.23M | $7.81M |
| Total liabilities | $97.7K | $2.61M | $2.78M | $2.87M | $2.27M | $978K | $1.15M | $797K | $1.53M | $2.24M |
| Shareholders' equity | -$2.27M | $373K | $9.70M | $8.01M | $22.9M | $25.5M | $7.47M | $4.99M | $1.70M | $5.58M |
| Retained earnings | -$2.00M | -$3.86M | -$7.62M | -$11.0M | -$25.4M | -$36.8M | -$64.2M | -$75.4M | -$87.2M | -$101M |
| Shares (wtd avg diluted) | 29.3M | 32.6M | 5.53M | 5.49M | 14.2M | 15.3M | 805K | 1.31M | 122K | 1.31M |
Every figure is extracted from Processa Pharmaceuticals, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.